Healthcare / BiotechnologyKOSDAQ
$1012.00
+4.00 (+0.40%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-10.0B · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
11/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$27.1B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-24.1%
↓Gross Margin
17.9%
↓Debt/Equity
1.45
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+24.5%
FCF CAGR
—
FCF margin
-40.6%
FCF / Net income
1.56x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $21.24B · net income $-5.54B · FCF $-8.62B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $21.24B | $21.24B | $5.61B | $4.35B | $11.02B |
| Net Income | $-5.54B | $-5.54B | $-12.98B | $-12.77B | $-9.79B |
| EBITDA | $-455.3M | $-455.3M | $-6.40B | $-10.05B | $-7.90B |
| EPS | -247.00 | -247.00 | -962.00 | -892.15 | -694.58 |
| Gross Margin | 17.9% | 17.9% | 37.3% | -3.2% | 37.6% |
| Operating Margin | -39.0% | -39.0% | -224.3% | -308.6% | -78.1% |
| Net Margin | -26.1% | -26.1% | -231.3% | -293.5% | -88.8% |
| Balance Sheet | |||||
| Debt/Equity | 1.45 | 1.45 | 0.53 | 0.70 | 0.45 |
| Current Ratio | 0.48 | 0.48 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-8.62B | $-8.62B | $-12.67B | $-9.99B | $-9.05B |
| Returns | |||||
| ROE | -24.1% | -24.1% | -76.4% | -78.4% | -38.7% |
| Valuation | |||||
| P/B | 0.99 | 0.99 | 1.36 | 4.91 | 5.62 |
| Growth & Yield | |||||
| Revenue Growth | 278.5% | 278.5% | 29.0% | -60.5% | — |
| EPS Growth | 74.3% | 74.3% | -7.8% | -28.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-47.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-962.00 → -247.00
Residual
-47.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.